Clinical Trial Search

Phase 3 N=274 Study of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV™) Compared to CD.JEVAX™ in Toddlers

Japanese Encephalitis · Japanese Encephalitis Virus Disease

Primary: Percentage of Participants With Seroconversion to Japanese Encephalitis Chimeric Virus Following Vaccination With Either IMOJEV™ or CD.JEVAX™ Japanese Encephalitis…

Sanofi Pasteur, a Sanofi Company Results Apr 2014 12.8% serious AE View details

Phase 3 N=52 Highdose Nicotine Patch Therapy for Smokeless Tobacco Use

Smokeless Tobacco Use

Primary: End of Treatment (Week 8) Point Prevalence Abstinence — 11; 6 participants — p=0.05

Mayo Clinic Results Apr 2014 1.9% serious AE View details

Phase 3 N=506 Varenicline and Bupropion for Smoking Cessation

Smoking

Primary: Prolonged Smoking Abstinence Rates at 12 Weeks in Cigarettes Smokers. — 132; 111 participants — p=0.03

Mayo Clinic Results Apr 2014 2.4% serious AE View details

Phase 3 N=18 Single Dosing of Zoledronic Acid in Cancer Therapy Induced Bone Loss (CTIBL)

Breast Cancer

Primary: Number of Participants With Urine and Serum NTx and Serum CTx Within Normal Range at 12 Months — 13 participants

Milton S. Hershey Medical Center Results Apr 2014 0.0% serious AE View details

Phase 3 N=657 Efficacy, Safety, and Tolerability of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

Primary: Trough Forced Expiratory Volume in 1 Second (FEV1) After 12 Weeks of Treatment (Non-inferiority Analysis) — 1.405; 1.405 Liters

Novartis Pharmaceuticals Results Apr 2014 3.7% serious AE View details

Phase 3 N=59 Clinical Trial of CNS-targeted HAART (CIT2)

HIV Infections

Primary: Neuropsychological Performance Change — -0.27; -0.17 units on a scale

University of California, San Diego Results Apr 2014 3.4% serious AE View details

Phase 3 N=425 Trial to Demonstrate the Efficacy and Safety of Conversion to Lacosamide Monotherapy for Partial-onset Seizures

Epilepsy

Primary: Percentage of Subjects (Using Kaplan-Meier) Who Are Identified As Meeting At Least 1 Pre-defined Exit Criteria By Day 112 Relative To The Start of Withdrawal of…

UCB BIOSCIENCES, Inc. Results Apr 2014 5.9% serious AE View details

Phase 3 N=393 An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy

Hepatitis C

Primary: The Percentage of Participants Achieving a Sustained Virologic Response 12 Weeks After the Planned End of Treatment (SVR12) — 79.2; 36.1 Percentage of participants…

Janssen R&D Ireland Results Apr 2014 6.4% serious AE View details

Phase 3 N=395 A Study to Evaluate the Effectiveness and Safety of a Fixed Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With High Blood Pressure Who do Not Achieve Target Blood Pressure Following Treatment With Azilsartan Medoxomil Alone

Essential Hypertension

Primary: Change From Baseline to Week 8 in Trough, Sitting, Clinic Systolic Blood Pressure — 150.7; 149.8; 149.8; -6.4 mm Hg — p=<0.001

Takeda Results Apr 2014 0.5% serious AE View details

Phase 3 N=71 Salsalate Therapy to Reduce Insulin Resistance and Cardiovascular Risk

Atherosclerosis · Cardiovascular Disease · Inflammation

Primary: Change in Systemic Glucose Disposal- Glucose Infusion Rates — 1; 6 percent change from baseline — p=<0.05

VA Office of Research and Development Results Apr 2014 0.0% serious AE View details

Phase 3 N=936 30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks

Diabetes Mellitus, Type 2

Primary: Change From Baseline in HbA1c After 30 Weeks of Treatment. — -0.66; -0.69; -0.87; -0.39 percent — p=0.1571

Boehringer Ingelheim Results Apr 2014 7.0% serious AE View details

Phase 3 N=570 24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms

Hot Flashes

Primary: Mean Change From Baseline in Hot Flash Frequency at Week 4 and Week 12. — 10.83; 10.90; -4.13; -2.71 Hot flashes per day — p=<0.0001

Noven Therapeutics Results Apr 2014 3.5% serious AE View details

Phase 3 N=251 Study to Evaluate 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) Vaccine Followed by 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients

Vaccines, Pneumococcal Conjugate Vaccine

Primary: Geometric Mean Fold Rise (GMFR) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody From Before 13vPnC Dose 1 to 1 Month After 13vPnC Dose 3 in All…

Pfizer Results Apr 2014 13.8% serious AE View details

Phase 3 N=180 A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus Infection

Chronic Hepatitis B Virus, Pediatric

Primary: Percentage of Participants Who Achieved a Combination of Hepatitis B Virus (HBV) DNA Suppression and Hepatitis B e Antigen (HBeAg) Seroconversion at Week 48 — 24.4; 2.4…

Bristol-Myers Squibb Results Apr 2014 7.2% serious AE View details

Phase 3 N=606 Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.

Pulmonary Disease, Chronic Obstructive

Primary: Change From Baseline in the Trough Forced Expiratory Volume in One Second (FEV1) on Day 85 — -0.001; 0.126; 0.147 Liters — p=<0.001

GlaxoSmithKline Results Apr 2014 4.5% serious AE View details